Drug delivery in multiple indication (multipurpose) prevention technologies: Systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission

Expert Opinion on Drug Delivery

Volumn 9, Issue 4, 2012, Pages 417-427

  Friend, David R ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Contraception; HIV 1 prevention; HSV 2 prevention; Multiple indication (multipurpose) prevention technologies

Indexed keywords

ACICLOVIR; DAPIVIRINE; ESTRADIOL; ESTRADIOL ACETATE; ETHINYLESTRADIOL PLUS ETONOGESTREL; FERTIRING; MICROBICIDE; PROGESTERONE; SILICONE; TENOFOVIR; UNCLASSIFIED DRUG;

CONTRACEPTION; DRUG DELIVERY SYSTEM; DRUG RELEASE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; MEDICAL TECHNOLOGY; MULTIPLE INDICATION PREVENTION TECHNOLOGY; NONHUMAN; PREGNANCY; REVIEW; SEXUALLY TRANSMITTED DISEASE; TABLET; VAGINA DISCHARGE; VIRUS TRANSMISSION;

ADENINE; ADMINISTRATION, INTRAVAGINAL; ANTI-INFECTIVE AGENTS; ANTIVIRAL AGENTS; BIOPHARMACEUTICS; CONTRACEPTION; DISEASE TRANSMISSION, INFECTIOUS; DRUG DELIVERY SYSTEMS; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; ORGANOPHOSPHONATES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY, UNPLANNED;

EID: 84858809948     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.668183     Document Type: Review

References (85)

1. Friend DR, Doncel GF. Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: Development of dual-protection technologies. Antiviral Res 2010;88(Suppl 1):S47-54 Comprehensive overview of dual-protection (multipurpose prevention) technologies.
2. Thurman AR, Clark MR, Doncel GF. Multipurpose prevention technologies: Biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol 2011;2011:1-10 Comprehensive overview of MIPTs.
3. Holt BY, Kilbourne-Brook M, Stone A, et al. Multipurpose prevention technologies for sexual and reproductive health: Gaining momentum and promise. Contraception 2010;81(3):177-80
4. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in Women. Science 2010;329(5996):1168-74 First report that a vaginal microbicide could significantly reduce sexual transmission of HIV-1 in women.
5. Nel A, Smythe S, Young K, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009;51(4):416-23
6. Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: A review of the literature [Article]. Eur J Contracept Reprod Health Care 2010;15(1):4-16
7. Cates WJMM, Steiner MJP. Dual protection against unintended pregnancy and sexually transmitted infections: What is the best contraceptive approach? [Editorial]. Sex Transm Dis 2002;29(3):168-74
8. Gollub EL. Choice is empowering: Getting strategic about preventing HIV infection in women. Int Fam Plan Perspect 2006;32(4):209-12
9. Berer M. Dual protection: More needed than practised or understood. Reprod Health Matters 2006;14(28):162-70
10. Brady M. Preventing sexually transmitted infections and unintended pregnancy, and safeguarding fertility: Triple protection needs of young women. Reprod Health Matters 2003;11(22):134-41
11. Chandran P, Kabir SN. Dual action microbicides: Reappraisal of their roles in contraceptive research. Reprod Biomed Online 2010;20(1):103-13
12. Baptista M, Ramalho-Santos J. Spermicides, microbicides and antiviral agents: Recent advances in the development of novel multi-functional compounds. Mini Rev Med Chem 2009;9(13):1556-67
13. Woolfson AD, Malcolm RK, Gallagher R. Drug delivery by the intravaginal route. Crit Rev Ther Drug Carrier Syst 2000;17(5):509-55
14. Gupta S, Gabrani R, Ali J, et al. Exploring novel approaches to vaginal drug delivery. Recent Pat Drug Deliv Formul 2011;5(2):82-94 Comprehensive review of vaginal drug delivery.
15. Yu T, Malcolm K, Woolfson D, et al. Vaginal gel drug delivery systems: Understanding rheological characteristics and performance. Expert Opin Drug Deliv 2011;8(10):1309-22
16. Whaley KJ, Hanes J, Shattock R, et al. Novel approaches to vaginal delivery and safety of microbicides: Biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res 2010;88(Suppl 1):S55-66
17. Kiser PF, Johnson TJ, Clark JT. State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev 2012;14(1):62-77
18. Vermani K, Garg S. The scope and potential of vaginal drug delivery. Pharm Sci Technol Today 2000;3(10):359-64
19. Fetherston SM, Malcolm RK, Woolfson AD. Controlled-release vaginal ring drug-delivery systems: A key strategy for the development of effective HIV microbicides. Ther Deliv 2010;1(6):785-802
20. Garg S, Goldman D, Krumme M, et al. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antiviral Res 2010;88(Suppl 1):S19-29
21. Romano J, Malcolm RK, Garg S, et al. Microbicide delivery: Formulation technologies and strategies. Curr Opin HIV AIDS 2008;3(5):558-66
22. Friend DR. Pharmaceutical development of microbicide drug products. Pharm Dev Technol 2010;15(6):562-81
23. Woolfson AD, Malcolm RK, Toner CF, et al. Potential use of vaginal rings for prevention of heterosexual transmission of HIV: A controlled-release strategy for HIV microbicides. Am J Drug Deliv 2006;4(1):7-20
24. Hardy E, Hebling EM, Sousa MH, et al. Delivery of microbicides to the vagina: Difficulties reported with the use of three devices, adherence to use and preferences. Contraception 2007;76(2):126-31
25. Nel AM, Mitchnick LB, Risha P, et al. Acceptability of vaginal film, soft-gel capsule, and tablet as potential microbicide delivery methods among African women [Article]. J Womens Health (15409996) 2011;20(8):1207-14
26. Pool R, Montgomery CM, Morar NS, et al. A Mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: The microbicides development programme [Article]. PLoS Clin Trials 2010;7(7):1-10
27. Tolley EE, Harrison PF, Goetghebeur E, et al. Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav 2010;14(5):1124-36 A unique study examining the acceptability of different vaginal dosage forms in African women.
28. Penman-Aguilar A, Swezey T, Turner AN, et al. Promoting continuous use of a strategy for achieving adherence in a trial of the diaphragm with candidate microbicide [Article]. AIDS Educ Prev 2009;21(6):512-25
29. Malcolm RK, Edwards KL, Kiser P, et al. Advances in microbicide vaginal rings. Antiviral Res 2010;88(Suppl 1):S30-9
30. Lete I, Duenas JL, Esplugues JV, et al. Is the vagina an adequate route for the administration of hormonal contraceptives? Curr Drug Metab 2010;11(10):839-49
31. Sarkar NN. Steroidal contraceptive vaginal rings. Int J Clin Pract 2003;57(5):392-5
32. Cleland J, Bernstein S, Ezeh A, et al. Family planning: The unfinished agenda. Lancet 2006;368(9549):1810-27
33. Sarkar NN. Low-dose intravaginal estradiol delivery using a Silastic vaginal ring for estrogen replacement therapy in postmenopausal women: A review. [Article]. Eur J Contracept Reprod Health Care 2003;8(4):217-24
34. van Laarhoven JA, Kruft MA, Vromans H. In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring. Int J Pharm 2002;232(1-2):163-73
35. van den Heuvel MW, van Bragt AJ, Alnabawy AK, et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: The vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005;72(3):168-74
36. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000;39(3):233-42
37. Ahrendt HJ, Nisand I, Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006;74(6):451-7
38. Novak A, de la Loge C, Abetz L, et al. The combined contraceptive vaginal ring, NuvaRing: An international study of user acceptability. Contraception 2003;67(3):187-94
39. Wieder DR, Pattimakiel L. Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing). Int J Womens Health 2010;2:401-9
40. Massai R, Quinteros E, Reyes MV, et al. Extended use of a progesterone-releasing vaginal ring in nursing women: A phase II clinical trial. Contraception 2005;72(5):352-7
41. Massai R, Miranda P, Valdes P, et al. Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women. Contraception 1999;60(1):9-14
42. Malcolm RK, Woolfson AD, Toner CF, et al. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 2005;56(5):954-6
43. Woolfson AD, Malcolm RK, Morrow RJ, et al. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm 2006;325(1-2):82-9
44. Van Herrewege Y, Michiels J, Van Roey J, et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 2004;48(1):337-9 Paper demonstrating the controlled release of DPV from silicone-based IVRs.
45. Nel AM, Smythe SC, Habibi S, et al. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr 2010;55(2):161-9
46. Nel AM, Coplan P, Smythe SC, et al. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses 2010;26(11):1181-90
47. Nel A, Smythe S, Young K, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009;51(4):416-23
48. Landgren BM, Aedo AR, Johannisson E, et al. Studies on a vaginal ring releasing levonorgestrel at an initial rate of 27 mcg/24 h when used alone or in combination with transdermal systems releasing estradiol. Contraception 1994;50(1):87-100
49. Van Herrewege Y, Michiels J, Van Roey J, et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides [Research Support, Non-U.S. Gov't]. Antimicrob Agents Chemother 2004;48(1):337-9
50. Di Fabio S, Van Roey J, Giannini G, et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 2003;17(11):1597-604
51. Szycher M. Biostability of polyurethane elastomers: A critical review. J Biomater Appl 1988;3(2):297-402
52. Clark MR, Johnson TJ, McCabe RT, et al. A hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781 [Article]. J Pharm Sci 2012;101(2):576-87
53. Gupta KM, Pearce SM, Poursaid AE, et al. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci 2008;97(10):4228-39
54. Johnson TJ, Gupta KM, Fabian J, et al. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci 2010;39(4):203-12
55. Karim SS, Kashuba AD, Werner L, et al. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: Implications for HIV prevention in women. Lancet 2011;378(9787):279-81
56. Johnson TJ, Albright TH, Clark MR, et al. Long-term, time-dependent release of the antiretroviral agent tenofovir in daily milligram quantities from an intravaginal ring [abstract No. 184]. 38th Annual Meeting & Exposition of the Controlled Release Society; 2011 A key paper assessing the relationship between pharmacokinetics and efficacy of oral and topical (gel) TFV for HIV-1 prevention.
57. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: A randomised, double-blind, placebo-controlled trial. Lancet 2008;371(9630):2109-19
58. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010;362(5):427-39
59. Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009;15(8):886-92
60. Kucera LS, Leake E, Iyer N, et al. Human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 2 (HSV-2) can coinfect and simultaneously replicate in the same human CD4+ cell: Effect of coinfection on infectious HSV-2 and HIV-1 replication. AIDS Res Hum Retroviruses 1990;6(5):641-7
61. Diaz JJ, Dodon MD, Schaerer-Uthurralt N, et al. Post-transcriptional transactivation of human retroviral envelope glycoprotein expression by herpes simplex virus Us11 protein. Nature 1996;379(6562):273-7
62. Heng MC, Heng SY, Allen SG. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet 1994;343(8892):255-8
63. Schacker T, Zeh J, Hu HL, et al. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998;178(6):1616-22
64. Mbopi-Keou FX, Gresenguet G, Mayaud P, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: Opportunities for intervention. J Infect Dis 2000;182(4):1090-6
65. Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004;190(8):1374-81
66. Andrei G, Lisco A, Vanpouille C, et al. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe 2011;10(4):379-89 This paper provides an explanation for the anti-HSV-2 transmission effects of TFV.
67. Moss JA, Malone AM, Smith TJ, et al. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother 2012;56(2):875-82
68. Kelly L, Carr D, Clark MR, et al. In vivo release in sheep of a dual loaded microbicide polyurethane vaginal ring. AAPS Annual Meeting and Exposition; 2011. p. T2258
69. Major I, Lowry D, Malcolm K, et al. Development of a microbicide- releasing diaphragm as an HIV prevention strategy. Conf Proc IEEE Eng Med Biol Soc 2010;2010:1089-92
70. Frezieres RG, Walsh T, Kilbourne-Brook M, et al. Couples' acceptability of the SILCS diaphragm for microbicide delivery. Contraception 2012;85(1):99-107
71. Wahren B, Biswas P, Borggren M, et al. Rational design of HIV vaccine and microbicides: Report of the EUROPRISE annual conference. J Transl Med 2010;8(1):72
72. Radomsky ML, Whaley KJ, Cone RA, et al. Controlled vaginal delivery of antibodies in the mouse. Biol Reprod 1992;47(1):133-40
73. Sherwood JK, Zeitlin L, Whaley KJ, et al. Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes. Nat Biotechnol 1996;14(4):468-71
74. Fuller AO, Spear PG. Anti-glycoprotein D antibodies that permit adsorption but block infection by herpes simplex virus 1 prevent virion-cell fusion at the cell surface. Proc Natl Acad Sci USA 1987;84(15):5454-8
75. Morrow RJ, Woolfson AD, Donnelly L, et al. Sustained release of proteins from a modified vaginal ring device. Eur J Pharm Biopharm 2011;77(1):3-10
76. Zhang T, Sturgis TF, Youan BB. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Eur J Pharm Biopharm 2011;79(3):526-36
77. Alukda D, Sturgis T, Youan BB. Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention. J Pharm Sci 2011;100(8):3345-56
78. Kang J-W, Davaa E, Kim Y-T, et al. A new vaginal delivery system of amphotericin B: A dispersion of cationic liposomes in a thermosensitive gel. J Drug Target 2010;18(8):637-44
79. Zalenskaya IA, Cerocchi OG, Joseph T, et al. Increased COX-2 Expression in human vaginal epithelial cells exposed to nonoxynol-9, a vaginal contraceptive microbicide that failed to protect women from HIV-1 infection. Am J Reprod Immunol 2011;65(6):569-77
80. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet 2002;360(9338):971-7 This paper describes the clinical results following use of nonoxynol-9 as a potential microbicide.
81. Damme LV. Clinical microbicide research: An overview. Trop Med Int Health 2004;9(12):1290-6
82. Dobaria N, Mashru R. Design and in vitro evaluation of a novel bioadhesive vaginal drug delivery system for clindamycin phosphate. Pharm Dev Technol 2010;15(4):405-14
83. Baloglu E, Ay Senyigit Z, et al. In Vitro evaluation of mucoadhesive vaginal tablets of antifungal drugs prepared with thiolated polymer and development of a new dissolution technique for vaginal formulations. Chem Pharm Bull 2011;59(8):952-8
84. Blish CA, Baeten JM. Hormonal contraception and HIV-1 transmission. Am J Reprod Immunol 2011;65(3):302-7
85. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: A prospective cohort study. Lancet Infect Dis 2011;11:11-26